The combination of both GLP-1 agonist and SGLT-2-inhibitor already showed remarkable improvements of the metabolic condition in the treatment of T2DM [8] and therefore seems to be a promising therapy concept for NASH and diabetes. The gene discussed is SLC5A2; the disease is metabolic dysfunction-associated steatohepatitis.